Claims for Patent: 7,713,938

Summary for Patent: 7,713,938

Title:	Crystalline form of 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy- )-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Abstract:	The invention relates to a crystalline form of 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.
Inventor(s):	Himmelsbach; Frank (Mittelbiberach, DE), Schmid; Sandra (Bad Wurzach, DE), Schuehle; Martin (Oberhoefen, DE), Martin; Hans-Jurgen (Biberach, DE), Eckhardt; Matthias (Biberach, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:	11/406,971
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,713,938
Patent Claims:	1. The crystalline form of 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-(S)-tetrahydrofuran-3-yloxy)- -benzyl]-benzene having an X-ray diffraction pattern that comprises peaks at 18.84, 20.36 and 25.21 degrees 2.theta..+-.0.05 degrees 2.theta., wherein said X-ray powder diffraction is made using CuK.sub..alpha.1 radiation. 2. The crystalline form according to claim 1, wherein the X-ray powder diffraction pattern further comprises peaks at 14.69, 19.16 and 19.50 degrees 2 .crclbar..+-.0.05 degrees 2 .crclbar., wherein said X-ray powder diffraction pattern is made using CuK.sub..alpha.1 radiation. 3. 1-Chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yl- oxy)-benzyl]-benzene, wherein at least 50% of said 1-Chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy- )-benzyl]benzene is present in the form of the crystalline form in accordance with claim 1. 4. A pharmaceutical composition comprising the crystalline form in accordance with claim 1. 5. A pharmaceutical composition comprising the crystalline form in accordance with claim 2. 6. A method for making the crystalline form in accordance with claim 1, said method comprising the following steps: (a) dissolving 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-]4-((S)-tetrahydrofuran-3-yloxy- )-benzyl]-benzene in a solvent or a mixture of solvents to form a saturated or nearly saturated solution; (b) storing the solution to precipitate the crystalline form in accordance with claim 2 out of solution and thus to yield a suspension; (c) isolating the precipitate from the suspension; and (d) drying the precipitate until any excess of said solvent or mixture of solvents has been removed. 7. A method for making the crystalline form in accordance with claim 2, said method comprising the following steps: (a) dissolving 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-]4-((S)-tetrahydrofuran-3-yloxy- )-benzyl]-benzene in a solvent or a mixture of solvents to form a saturated or nearly saturated solution; (b) storing the solution to precipitate the crystalline form in accordance with claim 3 out of solution and thus to yield a suspension; (c) isolating the precipitate from the suspension; and (d) drying the precipitate until any excess of said solvent or mixture of solvents has been removed.